These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 36892817)
41. Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Portincasa P; Bonfrate L; Khalil M; Angelis M; Calabrese FM; D'Amato M; Wang DQ; Di Ciaula A Biomedicines; 2021 Dec; 10(1):. PubMed ID: 35052763 [TBL] [Abstract][Full Text] [Related]
42. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota. Han R; Ma J; Li H Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233 [TBL] [Abstract][Full Text] [Related]
43. Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis. Plaza-Díaz J; Solis-Urra P; Aragón-Vela J; Rodríguez-Rodríguez F; Olivares-Arancibia J; Álvarez-Mercado AI Biomedicines; 2021 Feb; 9(2):. PubMed ID: 33546191 [TBL] [Abstract][Full Text] [Related]
44. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. Meroni M; Longo M; Dongiovanni P Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910 [TBL] [Abstract][Full Text] [Related]
45. Obesity, fatty liver disease and intestinal microbiota. Arslan N World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013 [TBL] [Abstract][Full Text] [Related]
46. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054 [TBL] [Abstract][Full Text] [Related]
47. Prebiotics and Probiotics: Therapeutic Tools for Nonalcoholic Fatty Liver Disease. Mijangos-Trejo A; Nuño-Lambarri N; Barbero-Becerra V; Uribe-Esquivel M; Vidal-Cevallos P; Chávez-Tapia N Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834367 [TBL] [Abstract][Full Text] [Related]
48. Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis. Yao N; Yang Y; Li X; Wang Y; Guo R; Wang X; Li J; Xie Z; Li B; Cui W Front Nutr; 2022; 9():906511. PubMed ID: 35782947 [TBL] [Abstract][Full Text] [Related]
49. NAFLD/MASLD and the Gut-Liver Axis: From Pathogenesis to Treatment Options. Vallianou NG; Kounatidis D; Psallida S; Vythoulkas-Biotis N; Adamou A; Zachariadou T; Kargioti S; Karampela I; Dalamaga M Metabolites; 2024 Jun; 14(7):. PubMed ID: 39057689 [TBL] [Abstract][Full Text] [Related]
50. Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. Li H; Wang Q; Chen P; Zhou C; Zhang X; Chen L Front Pharmacol; 2021; 12():788558. PubMed ID: 34938193 [TBL] [Abstract][Full Text] [Related]
51. Gut microbiota-mitochondrial inter-talk in non-alcoholic fatty liver disease. Zhang Q; Xing W; Wang Q; Tang Z; Wang Y; Gao W Front Nutr; 2022; 9():934113. PubMed ID: 36204383 [TBL] [Abstract][Full Text] [Related]
52. Microbiota, Fiber, and NAFLD: Is There Any Connection? Pérez-Montes de Oca A; Julián MT; Ramos A; Puig-Domingo M; Alonso N Nutrients; 2020 Oct; 12(10):. PubMed ID: 33053631 [TBL] [Abstract][Full Text] [Related]
53. Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol. Rahman K; Desai C; Iyer SS; Thorn NE; Kumar P; Liu Y; Smith T; Neish AS; Li H; Tan S; Wu P; Liu X; Yu Y; Farris AB; Nusrat A; Parkos CA; Anania FA Gastroenterology; 2016 Oct; 151(4):733-746.e12. PubMed ID: 27342212 [TBL] [Abstract][Full Text] [Related]
54. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. Cho MS; Kim SY; Suk KT; Kim BY J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993 [TBL] [Abstract][Full Text] [Related]
55. The role of the gut microbiota in NAFLD. Leung C; Rivera L; Furness JB; Angus PW Nat Rev Gastroenterol Hepatol; 2016 Jul; 13(7):412-25. PubMed ID: 27273168 [TBL] [Abstract][Full Text] [Related]
56. Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta-analysis. De Munck TJI; Xu P; Verwijs HJA; Masclee AAM; Jonkers D; Verbeek J; Koek GH Liver Int; 2020 Dec; 40(12):2906-2916. PubMed ID: 33037768 [TBL] [Abstract][Full Text] [Related]
57. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Zhou J; Tripathi M; Sinha RA; Singh BK; Yen PM Hepatoma Res; 2021; 7():11. PubMed ID: 33490737 [TBL] [Abstract][Full Text] [Related]
59. Constant Light Exposure Alters Gut Microbiota and Promotes the Progression of Steatohepatitis in High Fat Diet Rats. Wei L; Yue F; Xing L; Wu S; Shi Y; Li J; Xiang X; Lam SM; Shui G; Russell R; Zhang D Front Microbiol; 2020; 11():1975. PubMed ID: 32973715 [TBL] [Abstract][Full Text] [Related]
60. Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD. Jiang X; Zheng J; Zhang S; Wang B; Wu C; Guo X Front Med (Lausanne); 2020; 7():361. PubMed ID: 32850884 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]